(Circulation. 2000;102:2190.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway
From the Departments of Medicine and Pharmacology (N.J.B., J.V.G., L.J.M., D.E.V.), Vanderbilt University Medical Center, and the Nashville Veteran’s Administration Medical Center (D.E.V.), Nashville, Tenn.
Background—Bradykinin stimulates dose-dependent tissue plasminogen activator (tPA) release from human endothelium. Although bradykinin is known to cause vasodilation through B2 receptor–dependent effects on NO, prostacyclin, and endothelium-derived hyperpolarizing factor production, the mechanism(s) underlying tPA release is unknown.
Methods and Results—We measured the effects of
intra-arterial bradykinin (100, 200, and 400 ng/min),
acetylcholine (15, 30, and 60 µg/min), and nitroprusside (0.8, 1.6,
and 3.2 µg/min) on forearm vasodilation and tPA release in healthy
volunteers in the presence and absence of (1) the B2
receptor antagonist HOE 140 (100 µg/kg IV), (2) the NO
synthase inhibitor
L-NG-monomethyl-L-arginine
(L-NMMA, 4 µmol/min intra-arterially), and (3) the
cyclooxygenase inhibitor
indomethacin (50 mg PO TID). B2 receptor
antagonism attenuated vasodilator (P=0.004) and tPA
(P=0.043) responses to bradykinin, without attenuating
the vasodilator response to nitroprusside (P=0.36).
L-NMMA decreased basal forearm blood flow (from 2.35±0.31 to
1.73±0.22 mL/min per 100 mL, P=0.01) and blunted
the vasodilator response to acetylcholine (P=0.013) and
bradykinin (P=0.07, P=0.038 for forearm
vascular resistance) but not that to nitroprusside
(P=0.47). However, there was no effect of L-NMMA on
basal (P=0.7) or bradykinin-stimulated tPA release
(P=0.45). Indomethacin decreased urinary
excretion of the prostacyclin metabolite
2,3-dinor-6-keto-prostaglandin F1
(P=0.04). The vasodilator response to
endothelium-dependent (P=0.019 for
bradykinin) and endothelium-independent
(P=0.019) vasodilators was enhanced during
indomethacin administration. In contrast, there was no
effect of indomethacin alone (P=0.99) or
indomethacin plus L-NMMA (P=0.36) on
bradykinin-stimulated tPA release.
Conclusions—These data indicate that bradykinin stimulates tPA release from human endothelium through a B2 receptor–dependent, NO synthase–independent, and cyclooxygenase-independent pathway. Bradykinin-stimulated tPA release may represent a marker for the endothelial effects of endothelium-derived hyperpolarizing factor.
Key Words: bradykinin • endothelium • endothelium-derived factors • nitric oxide synthase • plasminogen activators
This article has been cited by other articles:
 |
|
 |
|
  C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway Hypertension, August 1, 2008; 52(2): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Guthmundsdottir, N. N. Lang, N. A. Boon, C. A. Ludlam, D. J. Webb, K. A. Fox, and D. E. Newby Role of the Endothelium in the Vascular Effects of the Thrombin Receptor (Protease-Activated Receptor Type 1) in Humans J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1749 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Astern, W. F. Pendergraft III, R. J. Falk, J. C. Jennette, A. H. Schmaier, F. Mahdi, and G. A. Preston Myeloperoxidase Interacts with Endothelial Cell-Surface Cytokeratin 1 and Modulates Bradykinin Production by the Plasma Kallikrein-Kinin System Am. J. Pathol., July 1, 2007; 171(1): 349 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Giannarelli, F. De Negri, A. Virdis, L. Ghiadoni, A. Cipriano, A. Magagna, S. Taddei, and A. Salvetti Nitric Oxide Modulates Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients Hypertension, April 1, 2007; 49(4): 878 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Drescher, H. Li, A. Lundgaard, C. Bunger, and E.-S. Hansen Endothelin-1-Induced Femoral Head Epiphyseal Artery Constriction Is Enhanced by Long-Term Corticosteroid Treatment J. Bone Joint Surg. Am., November 1, 2006; 88(suppl_3): 173 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Murphey, H. A. Malave, J. Petro, I. Biaggioni, D. W. Byrne, D. E. Vaughan, J. M. Luther, M. Pretorius, and N. J. Brown Bradykinin and Its Metabolite Bradykinin 1-5 Inhibit Thrombin-Induced Platelet Aggregation in Humans J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1287 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dhanasekaran, R. Al-Saghir, B. Lopez, D. Zhu, D. D. Gutterman, E. R. Jacobs, and M. Medhora Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H517 - H531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown Blood Pressure Reduction and Tissue-Type Plasminogen Activator Release Hypertension, April 1, 2006; 47(4): 648 - 649. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown, J. A.S. Muldowney III, and D. E. Vaughan Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition Hypertension, March 1, 2006; 47(3): 441 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S D Robinson, C A Ludlam, N A Boon, and D E Newby Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease Heart, February 1, 2006; 92(2): 170 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zamorano, S. Suchindran, and J. V. Gainer 3'-Untranslated region of the type 2 bradykinin receptor is a potent regulator of gene expression Am J Physiol Renal Physiol, February 1, 2006; 290(2): F456 - F464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Oliver, D. J. Webb, and D. E. Newby Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2470 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pretorius, J. M. Luther, L. J. Murphey, D. E. Vaughan, and N. J. Brown Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in Men Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2435 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Schrage, N. M. Dietz, J. H. Eisenach, and M. J. Joyner Agonist-dependent variablity of contributions of nitric oxide and prostaglandins in human skeletal muscle J Appl Physiol, April 1, 2005; 98(4): 1251 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L.M. Cruden, G. H. Tse, K. A.A. Fox, C. A. Ludlam, I. Megson, and D. E. Newby B1 Kinin Receptor Does Not Contribute to Vascular Tone or Tissue Plasminogen Activator Release in the Peripheral Circulation of Patients With Heart Failure Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 772 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L.M. Cruden, K. A.A. Fox, C. A. Ludlam, N. R. Johnston, and D. E. Newby Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition Hypertension, December 1, 2004; 44(6): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Shariat-Madar, F. Mahdi, and A. H. Schmaier Recombinant prolylcarboxypeptidase activates plasma prekallikrein Blood, June 15, 2004; 103(12): 4554 - 4561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L.M. Cruden, F. N. Witherow, D. J. Webb, K. A.A. Fox, and D. E. Newby Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1043 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Summar, J. V. Gainer, M. Pretorius, H. Malave, S. Harris, L. D. Hall, A. Weisberg, D. E. Vaughan, B. W. Christman, and N. J. Brown Relationship Between Carbamoyl-Phosphate Synthetase Genotype and Systemic Vascular Function Hypertension, February 1, 2004; 43(2): 186 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. N. Witherow, P. Dawson, C. A. Ludlam, D. J. Webb, K. A.A. Fox, and D. E. Newby Bradykinin Receptor Antagonism and Endothelial Tissue Plasminogen Activator Release in Humans Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1667 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, K. Minai, H. Horie, N. Ohira, H. Takashima, Y. Tarutani, Y. o Yasuda, T. Ozawa, S. Matsuo, M. Kinoshita, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1373 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pretorius, D. Rosenbaum, D. E. Vaughan, and N. J. Brown Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin Circulation, February 4, 2003; 107(4): 579 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T Smith, G. L Hoetzer, J. J Greiner, B. L Stauffer, and C. A DeSouza Effects of ageing and regular aerobic exercise on endothelial fibrinolytic capacity in humans J. Physiol., January 1, 2003; 546(1): 289 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Murphey, D. Vaughan, and N. Brown Contribution of bradykinin to the cardioprotective effects of ACE inhibitors Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A37 - A41. [Abstract] [PDF]
|
|
|
|
|
|
N. J. Brown, S. Kumar, C. A. Painter, and D. E. Vaughan ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time Hypertension, December 1, 2002; 40(6): 859 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. N. Witherow, P. Dawson, C. A. Ludlam, K. A. A. Fox, and D. E. Newby Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy J. Am. Coll. Cardiol., September 4, 2002; 40(5): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. S. Muldowney III and D. E. Vaughan Tissue-type plasminogen activator release: New frontiers in endothelial function J. Am. Coll. Cardiol., September 4, 2002; 40(5): 967 - 969. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Rosenbaum, M. Pretorius, J. V. Gainer, D. Byrne, L. J. Murphey, C. A. Painter, D. E. Vaughan, and N. J. Brown Ethnicity Affects Vasodilation, but Not Endothelial Tissue Plasminogen Activator Release, in Response to Bradykinin Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1023 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pretorius, D. A. Rosenbaum, J. Lefebvre, D. E. Vaughan, and N. J. Brown Smoking Impairs Bradykinin-Stimulated t-PA Release Hypertension, March 1, 2002; 39(3): 767 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Labinjoh, D. E. Newby, M. P. Pellegrini, N. R. Johnston, N. A. Boon, and D. J. Webb Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1402 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wilsdorf, J. V. Gainer, L. J. Murphey, D. E. Vaughan, and N. J. Brown Angiotensin-(1-7) Does Not Affect Vasodilator or TPA Responses to Bradykinin in Human Forearm Hypertension, April 1, 2001; 37(4): 1136 - 1140. [Abstract] [Full Text] [PDF]
|
|